ProNoxis AB
Developing small molecule drugs targeting NOX2 activation for inflammation treatment.
Oversigt
- 1
- Medarbejdere
- 212t SEK
- Omsætning
- 2008
- Grundlagt
Nøglebeslutningstagere
Peter Olofsson
Chairman & CEO
Beskrivelse
ProNoxis is a specialized biotechnology company focused on the preclinical exploration of novel small-molecule therapeutics. Its core mission is developing oral drugs to treat chronic inflammatory, autoimmune, and infectious diseases. The company targets a unique mechanism by developing agonists tha...
Tags
Nøgleord
Teknologistak
Virksomhedsoplysninger
- Branche
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE556773234101
Beslutningstagere
1 kontakter i FunnelfeedrPeter Olofsson
Chairman & CEO
Lignende virksomheder
20 lignende virksomheder i Funnelfeedr
Redoxis AB
19 medarbejdereSwedish CRO specializing in preclinical autoimmune and inflammatory disease models.
Inicure AB
0 medarbejdereDeveloping novel small molecules to combat resistant bacterial infections effectively.
Active Biotech AB (publ)
1–4 medarbejdereDeveloping novel treatments for cancer and inflammatory eye diseases.
VACARA AB
2 medarbejdereSwedish biotech developing RA diagnostics, vaccines, and therapeutics.
Novakand Pharma AB
5–9 medarbejdereDeveloping novel small-molecule drugs for inflammation and cancer.
Udforsk mere
Spørgsmål om ProNoxis AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo